Stockscreener 앱 받기
2.19
2.23%
-0.05
전일 마감가:
$2.24
열려 있는:
$2.25
하루 거래량:
6,354
Relative Volume:
0.03
시가총액:
$9.99M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-2.92
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
-0.90%
1개월 성능:
-10.25%
6개월 성능:
-71.19%
1년 성능:
-85.88%
1일 변동 폭
$2.20
$2.26
1주일 범위
$2.13
$2.34
52주 변동 폭
$1.98
$16.86
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.20 | 9.94M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.98 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
593.93 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.04 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.07 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
299.53 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan
Is Palisade Bio Inc. trending in predictive chart modelsMarket Activity Summary & Capital Protection Trade Alerts - Newser
Combining price and volume data for Nuvation Bio Inc.Dip Buying & Safe Swing Trade Setups - Newser
Is now a turning point for Adicet Bio Inc.July 2025 Update & AI Driven Price Predictions - Newser
GRI Bio Inc. stock prediction for this weekQuarterly Trade Report & Daily Stock Trend Reports - Newser
Is Palisade Bio Inc. stock ready for a breakoutBear Alert & Low Drawdown Momentum Trade Ideas - Newser
Will a bounce in Instil Bio Inc. offer an exitGold Moves & Weekly Chart Analysis and Guides - Newser
Stop Loss: Is Upstream Bio Inc. forming a double bottomJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - theviewers.co.kr
Layoff Tracker: Opthea Slashes 80% of Workforce, 50% of Board - BioSpace
Mustang Bio Inc. stock trend forecastJuly 2025 Summary & Verified Momentum Watchlists - Newser
Volume spikes in Palisade Bio Inc. stock – what they meanWeekly Market Outlook & Precise Swing Trade Alerts - Newser
Using economic indicators to assess Cabaletta Bio Inc. potentialWeekly Market Outlook & Low Volatility Stock Suggestions - Newser
Is Third Harmonic Bio Inc. building a consolidation baseJuly 2025 Catalysts & Long-Term Capital Growth Strategies - Newser
Heatmap analysis for Gossamer Bio Inc. and competitorsMarket Movers & Fast Exit Strategy with Risk Control - Newser
Combining price and volume data for Kronos Bio Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
Regression analysis insights on Gossamer Bio Inc. performanceBreakout Watch & High Return Trade Guides - Newser
Sentiment Tools Show Shift in Trader Mood on Cabaletta Bio Inc.2025 Sector Review & Community Driven Trade Alerts - beatles.ru
Gossamer Bio Inc.’s Beta Climbs After Market VolatilityJuly 2025 Summary & High Yield Stock Recommendations - classian.co.kr
GRI Bio CEO to Showcase NKT Cell Therapy Pipeline at Webull Biotech Investor Event - Stock Titan
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Is Tourmaline Bio Inc. stock ready for a breakoutFree Alpha Driven Watchlist With Alerts - Newser
Belite Bio Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Korro Bio Inc expected to post a loss of $2.56 a shareEarnings Preview - TradingView
Annovis Bio Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
MUSTANG BIO, INC. SEC 10-Q Report - TradingView
REPEATTevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions - uk.finance.yahoo.com
KALA BIO Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Instil Bio Inc expected to post a loss of $2.50 a shareEarnings Preview - TradingView
KALA BIO, Inc. SEC 10-Q Report - TradingView
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Q32 Bio Inc. Reports Continued Losses Amid Development Efforts - The Globe and Mail
INmune Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioVie Inc. Announces Pricing of $12 Million Public Offering - The Manila Times
Gossamer Bio Expands Team with 168,750 Share Options Grant at $2.16 Exercise Price - Stock Titan
INmune Bio Inc. Announces Second Quarter 2025 Results, - GlobeNewswire
INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes - Stock Titan
Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth - Stock Titan
Nuvation Bio Reports 1,043% YoY Sales Growth, Exceeds Revenue Estimates with $4.8 Million in GAAP Revenue - AInvest
Palisade Bio Reports 100% Clinical Response in Phase 1b - GlobeNewswire
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
New Lung Cancer Drug IBTROZI Gains FDA Approval, Reaches 70 Patients in First 7 Weeks - Stock Titan
How sentiment analysis helps forecast Instil Bio Inc.Insider Strategy for High Conviction Picks - Newser
Can technical indicators confirm Belite Bio Inc Depositary Receipt’s reversalFree Weekly Return Pick Forecast Reports - Newser
Pleno Inc. Announces First Commercial Agreement with Slopes Bio, Inc. - Bluefield Daily Telegraph
7 Dividend Stocks for 2025 — Some Pay Over 8%, Some Just Refuse to Die - The Globe and Mail
KALA BIO Showcases Breakthrough Eye Disease Treatments at Major Ophthalmology Conference - Stock Titan
Q32 Bio Secures FDA Fast Track for Alopecia Treatment as Phase 2 Trial Advances with $54.8M Runway - Stock Titan
Climb Bio Inc. stock daily chart insightsFree ROI Driven Equity Selection With Safety - Newser
Adicet Bio's Gamma Delta T Cell Therapy Updates Coming at Major Growth Conference - Stock Titan
INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial - Stock Titan
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
인에잇바이오 주식 (INAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCall Patrick | CHIEF FINANCIAL OFFICER |
Apr 30 '25 |
Option Exercise |
0.18 |
15,000 |
2,766 |
67,071 |
| Roemer Alan S. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
113,459 |
20,922 |
398,489 |
| Brandt Peter C. | Director |
Apr 30 '25 |
Option Exercise |
0.18 |
163,934 |
30,229 |
681,538 |
1.45%
7.60%
자본화:
|
볼륨(24시간):